Display options
Cite
Hotta Y, Kasuya H, Bustos I, et al. Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity. Oncolytic Virother. 2017;6:31-38doi: 10.2147/OV.S127179.
Hotta, Y., Kasuya, H., Bustos, I., Naoe, Y., Ichinose, T., Tanaka, M., & Kodera, Y. (2017). Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity. Oncolytic virotherapy, 631-38. https://doi.org/10.2147/OV.S127179
Hotta, Yoshihiro, et al. "Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity." Oncolytic virotherapy vol. 6 (2017): 31-38. doi: https://doi.org/10.2147/OV.S127179
Hotta Y, Kasuya H, Bustos I, Naoe Y, Ichinose T, Tanaka M, Kodera Y. Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity. Oncolytic Virother. 2017 Mar 13;6:31-38. doi: 10.2147/OV.S127179. eCollection 2017. PMID: 28331843; PMCID: PMC5357077.
Copy Download .nbib Format: NLM
Share it on

Oncolytic Virother. 2017 Mar 13;6:31-38. doi: 10.2147/OV.S127179. eCollection 2017.

Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity.

Oncolytic virotherapy

Yoshihiro Hotta, Hideki Kasuya, Itzel Bustos, Yoshinori Naoe, Toru Ichinose, Maki Tanaka, Yasuhiro Kodera

Affiliations

  1. Department of Surgery II.
  2. Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, Nagoya.
  3. Takara Bio Inc., Otsu, Japan.

PMID: 28331843 PMCID: PMC5357077 DOI: 10.2147/OV.S127179

Abstract

BACKGROUND: HF10 is a highly attenuated type 1 herpes simplex virus (HSV) with proven effective oncolytic effect. Previous investigations have demonstrated that colon cancer mice model treated with HF10 not only had better survival but were also resistant to the reimplantation of the antitumor effect mediated by host antitumor immunity. Importantly, it has also been noted that in mice with antitumors implanted on both sides of the back, an injection of HF10 on only one side strongly restrains not only the injected antitumor but also the non-injected ones.

MATERIALS AND METHODS: MC26 colon cancer cells were injected subcutaneously into the back, spleen, and intraperitoneal region of metastasis model mice. Antitumor volume and survival rate were monitored. To measure cytotoxic T lymphocytes (CTL) cytotoxicity against MC26, lymphocytes were extracted from the spleens of the peritoneal metastasis model mice as well as from the thymus of the liver metastasis model mice. The expression of interferon gamma was examined by enzyme-linked immunospot assay. Samples from the liver metastasis model mice were subjected to polymerase chain reaction to quantify the level of HSV genomes.

RESULTS: HF10 was injected only on the back antitumor; however, a antitumor-suppressor effect was observed against liver and peritoneal metastases. When HF10 genome was measured, we observed lower genome on liver metastases compared to back antitumor genome quantity. CTL activity against MC26 was also observed. These results indicate that local administration of HF10 exerts a curative effect on systemic disease, mediated by host antitumor immunity.

CONCLUSION: HF10 local administration stimulates antitumor immunity to recognize antitumor-specific antigen, which then improves systemic disease. Metastatic antitumors lysis, on the other hand, appears to be mediated by the host immune system, rather than by virus-mediated direct oncolysis.

Keywords: T-cell-mediated cytotoxicity; antitumor metastasis; herpes oncolytic virus; immune response

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1482-9 - PubMed
  2. Cancer Immunol Res. 2014 Apr;2(4):295-300 - PubMed
  3. J Clin Oncol. 2001 Jan 15;19(2):289-98 - PubMed
  4. Ann Surg. 2003 Jan;237(1):74-85 - PubMed
  5. Curr Cancer Drug Targets. 2007 Mar;7(2):157-67 - PubMed
  6. Int J Cancer. 2014 Jun 15;134(12):2865-77 - PubMed
  7. BioDrugs. 2016 Oct;30(5):461-468 - PubMed
  8. Cancer Res. 2001 Dec 15;61(24):8751-7 - PubMed
  9. Arch Virol. 2003 Apr;148(4):813-25 - PubMed
  10. Hepatogastroenterology. 2013 Mar-Apr;60(122):358-62 - PubMed
  11. Cancer Gene Ther. 2013 Sep;20(9):493-8 - PubMed
  12. Cancer Gene Ther. 2011 Mar;18(3):167-75 - PubMed
  13. J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 - PubMed
  14. Microbes Infect. 2007 Feb;9(2):142-9 - PubMed
  15. Adv Ther. 2016 Apr;33(4):643-57 - PubMed
  16. J Gastrointest Surg. 2009 Jul;13(7):1337-44 - PubMed
  17. Front Microbiol. 2012 Apr 30;3:158 - PubMed
  18. Science. 1991 May 10;252(5007):854-6 - PubMed
  19. Ann Surg Oncol. 2016 Dec;23 (13):4169-4177 - PubMed
  20. Cancer Res. 2002 Aug 15;62(16):4656-62 - PubMed
  21. Int J Cancer. 2013 Apr 1;132(7):1592-601 - PubMed
  22. Curr Cancer Drug Targets. 2007 Mar;7(2):169-74 - PubMed
  23. Ann Surg Oncol. 2006 Aug;13(8):1078-84 - PubMed
  24. Int J Cancer. 2015 Apr 1;136(7):1718-30 - PubMed
  25. Hepatogastroenterology. 2003 Jul-Aug;50(52):961-6 - PubMed
  26. Hepatogastroenterology. 2014 May;61(131):599-605 - PubMed
  27. Acta Otolaryngol. 2006 Oct;126(10):1115-7 - PubMed
  28. Ann Surg Oncol. 2014 Feb;21(2):691-8 - PubMed
  29. Front Oncol. 2014 Jul 21;4:188 - PubMed
  30. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 - PubMed

Publication Types